ADMS
$8.01
Adamas Pharma
$.01
.13%
ADMS
Earnings Whisper ®
N/A
3rd Quarter September 2021
Consensus:  ($0.22)
Revenue:  $25.07 Mil
Thursday
Nov 4
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Monday, August 9, 2021

What do you expect when ADMS reports earnings?
Beat
Meet
Miss

Where is ADMS's stock price going from here?
Up
Flat
Down
Stock chart of ADMS
Analysts
Summary of analysts' recommendations for ADMS
Score
Grade
Pivots
Resistance
$8.04
$8.02
$8.01

$7.99

Support
$7.98
$7.96
$7.95
Tweet
Growth
Description
Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson's disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company's portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas.
Peers
Vertex PharmaceuticalsUltragenyx PharmaceuticalRegeneron PharmaceuticalsBioMarin PharmaceuticalBristol-Myers SquibbInterCeptMerck & Co.Eli LillyZoetisPfizer